200 SMITH STREET, WALTHAM, MA
News, Articles of Incorporation, Bylaws
To be Acquired by ONO Pharmaceutical For $2.4 Billion
Annual Report to Security Holders
Fourth Quarter and Full Year 2023 Financial Results
Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company
Announces Third Quarter 2023 Financial Results
Announces Second Quarter 2023 Financial Results
Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer
Q1
FY 2023
Q3
Q2
FY 2022
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Solicitation/Recommendation Statement
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Schedule 14D-9C Solicitation/Recommendation Statement Communication
Additional Proxy Materials
Definitive Proxy Statement
PRER14A
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
S-8 POS